When it comes to the top biotech stocks to consider buying this month, as identified in today’s article, one has a virtual monopoly in its market and lots of cash. Another doesn’t have a monopoly, doesn’t have lots of cash, and doesn’t even have an approved drug on the market yet! What this small biotech does have, however, “is tremendous growth potential and at least one possible game-changer in its pipeline” – and while it’s the riskiest of the three stocks, it could also be the biggest winner. For more, CLICK HERE.